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Conclusion: Sequential chemotherapy and radiotherapy in 
adult medulloblastoma/PNET tumors is feasible with 
acceptable toxicity. High relapse rate in our patients indicate 
the need of treatment intensification with better 
coordination of combined therapy. 
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Purpose or Objective: Glioma is a primary brain tumour 
arising from the glial cells. High grade glioma, defined as 
grade III and IV, have poor survival rates. Glioblastoma 
multiforme is the commonest, but is also, the most 
aggressive type of glioma and is associated with a poor 
prognosis. Median survival of patients after treatment with 
debulking surgery followed by concurrent chemoradiotherapy 
and adjuvant chemotherapy is 14.6 months. Currently, post-
operative fractionated radiotherapy is prescribed to a range 
of 54 to 60 Gy in fractions of 2 Gy.  
Organs at risk (OARs) including optic chiasm, optic nerves and 
the brain stem, may lie within, or in close proximity to the 
PTV. Neuropathy and/or necrosis has been shown to occur 
when the maximum dose exceeds 55Gy in the optic chiasm 
and 54Gy to the whole brainstem. The standard practice at 
Rosemere Cancer Centre is to prioritise the OARs at the 
expense of the total dose, therefore prescribing to a dose of 
54Gy whenever the OARs is included in the PTV, which may 
have repercussions on tumour control and ultimately, overall 
survival.  
This retrospective analysis aims to compare patient outcomes 
between the 54Gy/57Gy and 59.4Gy/60Gy regimes, to 
determine if compromising the dose to spare OARs is 
detrimental to tumour control and survival. 
 
Material and Methods: The data of all glioma patients 
treated with radiotherapy between December 2012 and 
December 2014 at Rosemere Cancer Centre, were collected 
from our electronic databases. A total of 167 patients were 
identified. Patients with low grade glioma and those treated 
with a palliative intent were excluded. Fifty eight patients 
were included in the analysis. 
 
Results: Twenty one patients were on a lower dose 
radiotherapy regime of 54Gy or 57Gy. The remaining 37 were 
on a higher dose regime of 59.4Gy or 60Gy. There was a 
statistically significant difference (p=0.05) in patients treated 
with the higher dose regime comparatively, of an additional 
7.2 months median overall survival (mOS) benefit. The 
mortality hazard for the higher dose regime is 37% lower than 
the lower dose regime. 
 
Conclusion: The outcome of patients treated with the 
59.4/60Gy dose regime has shown to be statistically 
significant with a mOS benefit and lower mortality hazard. It 
is therefore clear that maintenance of the higher dose 
(59.4/60Gy) should be a priority, either at the expense of the 
OARs or to as much of the tumour volume as possible, whilst 
still observing the OARs constraints. 
 
EP-1129  
Pre and post-irradiation hypothalamic-pituitary axis 
dysfunction in adults treated for brain tumours 
N. Taku
1Addenbrooke’s Hospital - University of Cambridge, 
Department of Oncology, Cambridge, United Kingdom 
1, A. Powlson2, M. Romanchikova3, A. Hoole3, A. 
Bates1, J. Hale2, R. Jena1, M. Gurnell2, N. Burnet1 
2Addenbrooke’s Hospital - University of Cambridge, Institute 
of Metabolic Science, Cambridge, United Kingdom 
3Addenbrooke’s Hospital - University of Cambridge, 
Department of Medical Physics, Cambridge, United Kingdom 
 
Purpose or Objective: Collateral irradiation of normal 
structures during whole brain radiotherapy increases the risk 
of secondary toxicities, including dysfunction of the 
hypothalamic-pituitary axis (HPA). In studies of children 
treated for intracranial neoplasms, Merchant et al. showed 
that upwards of 66% of patients had pre-irradiation 
endocrinopathies and that HPA dosimetry data can be used to 
predict the dose-volume effects of radiation on growth 
hormone (GH) secretion. However, no comparable endocrine 
studies have been performed in adult populations. Evidence 
exists to suggest that hypopituitarism is an independent risk 
factor for mortality in adults treated with whole brain 
radiotherapy. Increased collaboration between radiation 
oncologists and endocrinologists is needed to amalgamate 
dosimetry data with the results of endocrine testing and 
better characterize HPA dysfunction. The purpose of this 
study is to determine the presence of baseline HPA 
dysfunction as well as the time to onset and dose-
dependence of post-irradiation HPA dysfunction in adults 
treated for non-pituitary brain tumours. 
 
Material and Methods: Twelve patients, 3 males and 9 
females, have been enrolled in our prospective clinical study 
that will continue to recruit until 2017. Primary diagnoses 
included meningioma (7), pineal tumor (3), and glioma (2). 
Median patient age is 52 (range 23-71). Enrolled patients 
have undergone comprehensive baseline endocrine testing of 
the thyroid, gonadotropins, cortisol, prolactin, and GH prior 
to initiation of radiotherapy. Patients have received daily 
image guidance imaging with positional correction and 50-60 
Gy of radiation to the tumour bed. Parametisation of 
available dosimetry data was performed to determine the 
maximum, minimum, and mean radiation doses. Endocrine 
testing is being repeated at 6 month intervals following 
radiotherapy. Patient reported outcome measures are also 
collected during follow-up encounters. Reviewing 
endocrinologists have been blinded to dosimetry data. 
 
Results: Three patients (25%) demonstrated pre-irradiation 
endocrinopathies, including 2 cases of primary 
hypothyroidism and 1 case of primary hypogonadism. 
Furthermore, one patient exhibited temporary HPA 
suppression secondary to exogenous steroid use. Median 
length to endocrinology follow-up is still short at only 3 
months (range 0-18). We present analyzed dose data for 10 of 
the 12 patients. Mean radiation doses to the hypothalamus 
and pituitary were 35 Gy (range 20-55) and 31 Gy (range 13-
50), respectively. No cases of new, radiation-related HPA 
dysfunction have been identified to date. 
 
Conclusion: The incidence of pre-irradiation HPA dysfunction 
underlines the need for baseline endocrinology studies. The 
range of radiation doses to the HPA should allow for 
identification of dose-volume responses.  
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Purpose or Objective: Present and retrospectively evaluate 
our protocol of WBRT + SIB regarding radiation-induced 
alopecia 
 
Material and Methods: We use masks type 35764 / 2MA / M 
Orfit a subnet mask with eXaskin and compatible base 
resonance (eXaFrame). A similar number of slices is used in 
the images of CT and MRI, both acquisitions with identical 
position and immobilization and slice thickness of 1 mm. This 
is possible thanks to eXaFrame, resulting in excellent quality 
